TY - JOUR
T1 - Radiotherapy planning and molecular imaging in lung cancer
AU - Filice, Angelina
AU - Casali, Massimiliano
AU - Ciammella, Patrizia
AU - Galaverni, Marco
AU - Fioroni, Federica
AU - Iotti, Cinzia
AU - Versari, Annibale
N1 - Funding Information:
We would like to acknowledge and thank our study coor-dinator, Chiara Coruzzi, for the precious help she gave us in carrying out this work and Dr Laura Evangelista for her con-stant support and collaboration during the writing of this paper.
Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - Introduction: In patients suitable for radical chemoradiotherapy for lung cancer,18F-FDG-PET/CT is a proposed management to improve the accuracy of high dose radiotherapy. However, there is a high rate of locoregional failure in patients with locally advanced non-small cell lung cancer (NSCLC), probably due to the fact that standard dosing may not be effective in all patients. The aim of the present review was to address some criticisms associated with the radiotherapy image-guided in NSCLC. Materials and Methods: A systematic literature search was conducted. Only published articles that met the following criteria were included: articles, only original papers, radiopharmaceutical ([18F]FDG and any tracer other than [18F]FDG), target, only specific for lung cancer radiotherapy planning, and experimental design (eventually “in vitro” studies were excluded). Peer-reviewed indexed journals, re-gardless of publication status (published, ahead of print, in press, etc.) were included. Reviews, case reports, abstracts, editorials, poster presentations, and publications in languages other than English were excluded. The decision to include or exclude an article was made by consensus and any dis-agreement was resolved through discussion. Results: Hundred eligible full-text articles were assessed. Diverse information is now available in the literature about the role of FDG and new alternative radiopharmaceuticals for the planning of radiotherapy in NSCLC. In particular, the role of alternative technologies for the segmentation of FDG uptake is essential, although indeterminate for RT planning. The pros and cons of the available techniques have been extensively reported. Conclusion: PET/CT has a central place in the planning of radiotherapy for lung cancer and, in par-ticular, for NSCLC assuming a substantial role in the delineation of tumor volume. The development of new radiopharmaceuticals can help overcome the problems related to the disadvantage of FDG to ac-cumulate also in activated inflammatory cells, thus improving tumor characterization and providing new prognostic biomarkers.
AB - Introduction: In patients suitable for radical chemoradiotherapy for lung cancer,18F-FDG-PET/CT is a proposed management to improve the accuracy of high dose radiotherapy. However, there is a high rate of locoregional failure in patients with locally advanced non-small cell lung cancer (NSCLC), probably due to the fact that standard dosing may not be effective in all patients. The aim of the present review was to address some criticisms associated with the radiotherapy image-guided in NSCLC. Materials and Methods: A systematic literature search was conducted. Only published articles that met the following criteria were included: articles, only original papers, radiopharmaceutical ([18F]FDG and any tracer other than [18F]FDG), target, only specific for lung cancer radiotherapy planning, and experimental design (eventually “in vitro” studies were excluded). Peer-reviewed indexed journals, re-gardless of publication status (published, ahead of print, in press, etc.) were included. Reviews, case reports, abstracts, editorials, poster presentations, and publications in languages other than English were excluded. The decision to include or exclude an article was made by consensus and any dis-agreement was resolved through discussion. Results: Hundred eligible full-text articles were assessed. Diverse information is now available in the literature about the role of FDG and new alternative radiopharmaceuticals for the planning of radiotherapy in NSCLC. In particular, the role of alternative technologies for the segmentation of FDG uptake is essential, although indeterminate for RT planning. The pros and cons of the available techniques have been extensively reported. Conclusion: PET/CT has a central place in the planning of radiotherapy for lung cancer and, in par-ticular, for NSCLC assuming a substantial role in the delineation of tumor volume. The development of new radiopharmaceuticals can help overcome the problems related to the disadvantage of FDG to ac-cumulate also in activated inflammatory cells, thus improving tumor characterization and providing new prognostic biomarkers.
KW - F-FDG-PET/CT
KW - Lung cancer
KW - Motion artifacts
KW - New radiopharmaceuticals
KW - Radiotherapy planning
KW - Target volume definition
UR - http://www.scopus.com/inward/record.url?scp=85096167018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096167018&partnerID=8YFLogxK
U2 - 10.2174/1874471013666200318144154
DO - 10.2174/1874471013666200318144154
M3 - Review article
C2 - 32186275
AN - SCOPUS:85096167018
SN - 1874-4710
VL - 13
SP - 204
EP - 217
JO - Current Radiopharmaceuticals
JF - Current Radiopharmaceuticals
IS - 3
ER -